Department of Pharmacy, Uppsala University, Uppsala 75233, Sweden.
Pharmaceutical Technology & Development Inhalation, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
Eur J Pharm Biopharm. 2018 Mar;124:1-12. doi: 10.1016/j.ejpb.2017.11.013. Epub 2017 Nov 27.
Permeation of inhaled drugs across the pulmonary epithelium can regulate the rate and extent of local drug absorption and hence the pulmonary tissue concentration. Therefore, understanding pulmonary epithelial transport could be important for successful design of novel inhaled medicines. To enhance understanding of pulmonary epithelial transport, drug transport data were generated for a set of inhaled compounds (n = 10) in the single-pass, isolated perfused rat lung model. A compartmental in silico model was used to estimate pulmonary permeability and tissue retention. The theoretical model was also used to re-analyze previously obtained historical drug transport data from the isolated perfused lung (n = 10) with re-circulating buffer. This was performed to evaluate the re-circulating model for assessing tissue retention measurements and to increase the number of data points. The tissue retention was an important parameter to estimate to be able to describe the drug transport profiles accurately of most of the investigated compounds. A relationship between the pulmonary permeability and the intrinsic (carrier-mediated transport inhibited) permeability of Caco-2 cell monolayers (n = 1-6) was also established. This correlation (R = 0.76, p < .0001) suggests that intrinsic Caco-2 permeability measurements could offer early predictions of the passive transcellular permeability of lung epithelium to candidate drugs. Although, for some compounds a deviation from the correlation suggests that other transport mechanisms may coexist. The compartmental in silico model was successful in describing the pulmonary drug transport profiles of the investigated compounds and has potential for further development to investigate the effects of formulations with different features on the pulmonary overall absorption rate.
吸入药物穿过肺上皮的渗透作用可以调节局部药物吸收的速率和程度,从而影响肺部组织的药物浓度。因此,了解肺上皮的转运机制对于成功设计新型吸入药物可能非常重要。为了增强对肺上皮转运的理解,我们在单次通过的离体灌注大鼠肺模型中为一组吸入化合物(n=10)生成了药物转运数据。使用房室体内模型来估计肺通透性和组织保留。该理论模型还用于重新分析以前从具有再循环缓冲液的离体灌注肺中获得的历史药物转运数据(n=10),以评估再循环模型是否可以用于评估组织保留测量并增加数据点数量。组织保留是一个重要的参数,需要对其进行估计,以便能够准确描述大多数研究化合物的药物转运特征。还建立了肺通透性与 Caco-2 细胞单层的内在(载体介导的转运抑制)通透性之间的关系(n=1-6)。这种相关性(R=0.76,p<0.0001)表明,内在 Caco-2 通透性测量值可以为候选药物的肺上皮被动跨细胞通透性提供早期预测。尽管对于某些化合物,存在偏离相关性的情况,这表明可能存在其他转运机制。房室体内模型成功地描述了所研究化合物的肺药物转运特征,并且具有进一步发展的潜力,可以研究不同特征的制剂对肺整体吸收速率的影响。